HDAC9 and acute lymphoblastic leukemia: In clinical trials of patients with relapsed/refractory ALL, HDAC inhibitors, including panobinostat and vorinostat, are being investigated alone (NCT00723203) or in combination with chemotherapy (NCT01321346, NCT02518750) or bortezomib (NCT02553460, NCT01312818).